Specific binding sites for gonadotrophin-releasing hormone, LH/chorionic gonadotrophin, low-density lipoprotein, prolactin and FSH in homogenates of human corpus luteum. II: Concentrations throughout the luteal phase of the menstrual cycle and early pregnancy.
Specific binding sites for gonadotrophin-releasing hormone, LH/chorionic gonadotrophin, low-density lipoprotein, prolactin and FSH in homogenates of human corpus luteum. II: Concentrations throughout the luteal phase of the menstrual cycle and early pregnancy.
复制标题
人黄体匀浆中促性腺激素释放激素、LH/绒毛膜促性腺激素、低密度脂蛋白、催乳素和 FSH 的特异性结合位点。
DOI：
10.1677/joe.0.1130317
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
D. Baird
中科院分区：
文献类型：
--
作者：
T. Bramley;D. Stirling;I. Swanston;G. Menzies;A. McNeilly;D. Baird
从52名在月经周期黄体期进行剖腹手术的妇女身上获得黄体。此外，从7名在周期的卵泡-排卵前晚期接受卵巢切除的妇女身上获得了间质、膜和颗粒细胞。在优化的条件下，测定了~(125)I标记的促性腺激素释放激素(GnRH)激动剂[D-Ser(BUT)6]GnRH(1-9)-乙胺(Buserelin)和人绒毛膜促性腺激素(HCG)、人FSH(HFSH)、人催乳素(HPRL)和人低密度脂蛋白(HLDL)与组织匀浆的特异性结合。结合的黄体生成素/人绒毛膜促性腺激素用酸-柠檬酸缓冲液洗脱，然后用放射免疫法测定释放的激素。促性腺激素释放激素激动剂的结合率虽然不同，但在黄体中期的结合率最高，在妊娠黄体的四分之三也存在高结合率。促黄体生成素/人绒毛膜促性腺激素结合随着黄体化程度的增加而显著增加，在黄体中期达到最大值，之后显著下降。在整个黄体期，结合的黄体激素受体的占有率相对恒定(10.7-35.3%)，但从早孕开始黄体的占有率增加到90%以上。HFSH的结合是可变的，50个黄体中只有5个结合超过10pg/微克DNA。类似地，hPRL结合量变化很大，44个中只有6个结合量大于50pg/微克DNA。低密度脂蛋白的结合率在黄体周期的早、中期最高。在月经周期各阶段的黄体中(不包括白体)，促性腺激素释放激素激动剂的结合量与未被占用和已被占用的黄体黄体中的黄体激素受体水平呈高度正相关(P<0.001；P<0.002；n=49)。GnRH激动剂的结合也与PRL结合相关(P<0.05；n=21)，但与FSH受体的结合无关(P>0.4；n=25)。低密度脂蛋白与催乳素(P<0.005.0 5；n=2 1)、促卵泡刺激素受体(P<0.0 5；n=2 5)和内源性结合的黄体生成素(P<0.0 3；n=48)有关，但与未被占用的黄体生成素受体无关(P=0.8；n=49)。此外，在黄体中期的黄体中，GnRH激动剂与低密度脂蛋白受体的结合有很强的相关性(P<0.02；n=23)。GnRH激动剂结合与黄体功能的一些重要指标之间的相关性表明，GnRH样因子在人黄体中具有生理作用。
Corpora lutea were obtained from 52 women undergoing laparotomy during the luteal phase of the menstrual cycle. In addition, stromal, thecal and granulosa cell preparations were obtained from seven women undergoing ovariectomy during the late follicular-preovulatory phase of the cycle. The specific binding of a 125I-labelled gonadotrophin-releasing hormone (GnRH) agonist [D-Ser(But)6] GnRH(1-9)-ethylamide (buserelin) and of human chorionic gonadotrophin (hCG), human FSH (hFSH), human prolactin (hPRL) and human low-density lipoprotein (hLDL) to tissue homogenates was measured under optimal conditions. Bound LH/hCG was estimated by elution with acid-citrate buffer, followed by radioimmunoassay of released hormone. Binding of GnRH agonist, though variable, was highest in mid-luteal corpus luteum and high binding was also present in three out of four corpora lutea of pregnancy. Binding of LH/hCG increased significantly with luteinization, reaching maximal levels in the mid-luteal phase before falling significantly. Occupancy of LH receptors by bound LH was relatively constant throughout the luteal phase (10.7-35.3%), but occupancy increased to greater than 90% in corpora lutea from early pregnancy. Binding of hFSH was variable, with only five out of 50 corpora lutea having binding greater than 10 pg/micrograms DNA. Similarly, hPRL binding varied markedly with only six out of 44 having binding greater than 50 pg/micrograms DNA. Binding of LDL was highest in the early- to mid-luteal phases of the cycle. In corpora lutea from all stages of the menstrual cycle (excluding corpora albicantia), GnRH agonist binding was highly correlated with the levels of unoccupied and occupied LH receptors (P less than 0.001; n = 49 and n = 48 respectively) and with LDL receptors (P less than 0.002; n = 49). Binding of GnRH agonist was also correlated with PRL binding (P less than 0.05; n = 21) but not with FSH receptors (P greater than 0.4; n = 25). In addition, LDL binding was associated with PRL (P less than 0.005; n = 21) and FSH receptors (P less than 0.05; n = 25) and with endogenously bound LH (P less than 0.03; n = 48), but not with unoccupied LH receptors (P = 0.8; n = 49). Moreover, in corpora lutea from the mid-luteal phase, there was a strong association between GnRH agonist binding and LDL receptors (P less than 0.02; n = 23). The correlations between GnRH agonist binding and a number of important indices of luteal function suggest a physiological role for GnRH-like factors in the human corpus luteum.